LLY
2026Q2BMOEli Lilly and Company primary · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Street
Consensus EPS6.01
Consensus rev—
EPS high—
EPS low—
Dispersion—
Analysts—
EPS rev net 7d—
EPS rev net 30d—
Consensus Δ 7d—
Consensus Δ 30d—
Options
Implied move2.7%
IV front—
P/C full—
P/C front—
Features as of2026-08-04
Run-up
Close—
Ret 5d-8.6%
Ret 10d-5.1%
Ret 20d-9.7%
Ret 30d+1.2%
Actual EPS
8.38Beat
Estimated EPS6.01
Actual revenue
23.0B
Surprise %+39.4%
Beat / missBeat
Beat streak 44
Beat streak 85
Reaction
1-day stock reaction-0.4%
Implied vs actual
Implied 2.7%Actual 5.2%
Gap reaction+5.2%
Day result+4.9%
Next-day upNo
Realized / IV1.93×
Post tape
Post 5d+4.3%
Post 10d+9.4%
Post volume6.4M
Vol ×10d2.63×
Vol ×20d2.64×
Post range6.7%